Group 1 - The core point of the article is that China Resources Double Crane has received approval from the National Medical Products Administration for its peritoneal dialysis solution, indicating a significant development in its product portfolio [1] - The peritoneal dialysis solution is primarily used for patients with acute and chronic renal failure, highlighting the company's focus on critical healthcare needs [1] - The company has invested a total of 1.2174 million yuan in research and development for this product, reflecting its commitment to innovation in the pharmaceutical sector [1] Group 2 - The global market size for peritoneal dialysis solutions (lactate) is projected to be approximately 5.62 billion USD in 2024, indicating a substantial market opportunity [1] - The domestic sales total for peritoneal dialysis solutions is estimated at 2.78 billion yuan, showcasing the potential for growth in the local market [1] - China Resources Double Crane's sales revenue from this product line is reported at 317 million yuan, capturing a market share of 14%, which positions the company competitively within the industry [1]